Myasthenia Gravis: Predicting Patient Response to Precision Medicine

Here’s a ⁤cleaned-up version of the text, removing the extraneous code while preserving the content and links:

(MG). They⁤ discuss important considerations in the move toward a ‌precision medicine approach⁢ in the space⁢ that ⁢include⁢ MG immunopathologic basis, ‌defining disease subgroup, and patient comorbidities.

Bhavaraju-Sanka is‍ the John H. Doran, MD, FACP, Endowed Chair in Peripheral⁣ Neuropathy at UT Health San Antonio, ⁢and Stein ‌is the⁢ chief of neurology⁣ at St. Joseph’s Health.

Rewatch part 1 of their ⁢interview to learn about ensuring broad access to new MG treatments and part ‍2 where ⁢they address​ the ‍roles of holistic care⁤ and‍ patient-physician collaboration.

This transcript was lightly​ edited ⁢for content.

Key changes⁤ made:

* Removed all the <astro-island> tags and associated​ attributes.
* converted the link-related code‍ within those ⁢tags into standard Markdown links: [link text](URL).
* ⁤ Preserved‍ the text content and the links themselves.
* Removed the initial 0,"24da83a1ff3e"]} which appeared to be extraneous.